Investigational Therapeutics That Restore Brain Synapses
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
Unique Approaches for Conditions Involving the Loss or Dysfunction of Brain Synapses
Patent-protected compound
Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X syndrome and many others.
Latest Press Releases
Spinogenix Reports Evidence of Rapid, Sustained Cognitive Improvement in Alzheimer’s Patients from Phase 2a Trial of TAZBENTETOL (formerly SPG302)
December 8, 2025
Tazbentetol, a Potential First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Showed a Favorable Safety Profile and Promising Benefits in Multiple Outcome Measures. Subset Exhibited Significant Improvement in AD-Related Brain Activity, As...
Spinogenix Announces World Health Organization Approval of ‘tazbentetol’ as International Non-Proprietary Name for SPG302
December 1, 2025
Tazbentetol is a First-in-Class, Synaptic Regenerative Investigation Therapy for Alzheimer’s disease, ALS, Schizophrenia and Glaucoma
Spinogenix Presents Topline Phase 2a Clinical Trial Results for SPG302, a First-in-Class ALS Treatment
November 4, 2025
The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients
In the News
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
December 9, 2025
Topline data from a completed phase 2a trial (NCT05882695) highlighted the therapeutic benefits of SPG302, a synaptic regenerative drug, to treat patients with amyotrophic lateral sclerosis (ALS). All told, treatment...
From the Blog
Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
December 1, 2025
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our...